 cisplatin treatment non-smal cell lung cancer southwest oncolog group studi novobiocin avail oral antibiot dna topoisomeras II manner cell cultur cytotox agent cisplatin thirty-six patient phase II trial high-dos cisplatin day cycl steady-st dose novobiocin mg capsul hour dose dose cisplatin patient studi respons complet respons patient partial respons addit patient unconfirm partial respons median surviv time patient month result compar concurr southwest oncolog group swog phase II iii trial high-dos cisplatin non-smal cell lung cancer nsclc novobiocin plasma level patient optim concentr cell cultur potenti cytotox optimum test novobiocin modul cytotox avail intraven prepar